NCT03918343 (MetAlloLip) is a NA clinical trial of Blood sample in Hematologic Diseases, sponsored by Centre Hospitalier Universitaire de Besancon.

Who is sponsoring NCT03918343?

NCT03918343 is sponsored by Centre Hospitalier Universitaire de Besancon.

What drugs are being tested in NCT03918343?

Interventions in NCT03918343: Blood sample.

What condition does NCT03918343 study?

NCT03918343 studies Hematologic Diseases, Stem Cell Transplantation.

Is NCT03918343 still recruiting?

NCT03918343 is currently completed. Last updated 9 July 2025.

Last reviewed 2025-07-09 · How we verify

NCT03918343: MetAlloLip

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation

Completed NA Last updated 9 July 2025

What this trial tests

NA trial testing Blood sample in Hematologic Diseases in 95 participants. Completed in 23 May 2025.

Timeline

6 September 2019

Primary endpoint
1 September 2024

23 May 2025

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Besancon
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	95
Start date	6 September 2019
Primary completion	1 September 2024
Estimated completion	23 May 2025
Sites	2 locations across France

Drugs / interventions tested

Blood sample — full drug profile →

Conditions studied

Hematologic Diseases — all drugs for Hematologic Diseases →
Stem Cell Transplantation — all drugs for Stem Cell Transplantation →

Sponsor

Centre Hospitalier Universitaire de Besancon

Who can join

Adults 18 to 85, any sex, with Hematologic Diseases or Stem Cell Transplantation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to assess the hypothesis that the lipopolysaccharide (LPS) activity index can be quantified early after transplantation, as well as the the PhosphoLipid Transfer Protein (PLTP) activity and these both biological variables are independent variables for predicting the risk of severe Graft versus Host Disease (GVHD).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Applications of gut microbiota in patients with hematopoietic stem-cell transplantation.
Yu J, Sun H, Cao W, Han L, et al · · 2020 · cited 19× · PMID 33292670 · DOI 10.1186/s40164-020-00194-y
The role of the intestinal microbiota in allogeneic HCT: clinical associations and preclinical mechanisms.
Nguyen CL, Docampo MD, van den Brink MR, Markey KA. · · 2021 · cited 14× · PMID 33388483 · DOI 10.1016/j.gde.2020.11.007

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

NCT07226466 — Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07030205 — Resting-state Imaging and OSteoporosiS · NA · recruiting
NCT07295808 — Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) · NA · recruiting

Other recruiting trials for Hematologic Diseases

Currently open trials in the same condition.

NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting
NCT05414045 — Autologous Testicular Tissue Transplantation · NA · recruiting
NCT06613425 — Clinical Study of Combined Platelet Transfusion · Phase 4 · recruiting
NCT06271252 — A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · Phase 1 · recruiting

Other Centre Hospitalier Universitaire de Besancon trials

Trials by the same sponsor.

NCT07492199 — High Depth Exome Sequencing on DNA From a Salivary Sample by Mouth Smear. · not yet recruiting
NCT07438015 — VEXUS-REA : Evaluation of Ultrasound Parameters of Venous Congestion in Patients in a Medical Intensive Care Unit · NA · not yet recruiting
NCT06796114 — Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Du · NA · recruiting
NCT06864065 — Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder · NA · recruiting
NCT07067762 — Botulinum Toxin Injections Into the Salivary Glands of Cerebrospinal Children With Chronic Sialorrhea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03918343 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Besancon
Last refreshed: 9 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03918343.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing